News

Endo Pharma intends to finance the deal with $500m from its balance sheet, while securing a $300m credit line and tapping an additional $400m financing. Endo Pharma, a

RBC said that this appointment is the result of the step down of Mike Zaleski as RBC’s president and CEO effective 22 October 2010. Prior to joining RBC,

The primary endpoint will be the ACR20 response rate, the standard primary endpoint for RA clinical trials. Galapagos intends to declare the interim results by the middle of

With the support of grants from the Alberta Livestock and Meat Agency and Genome Canada, Chronix is working in partnership with the University of Calgary to develop a

Sort Out IV, a randomised trial, was designed to test whether the Xience V stent is non-inferior to the Cypher stent. Reportedly, both drug-eluting stents performed better than

VaxDesign is the developer of the Modular IMmune In-vitro Construct (MIMIC) technology that melds immunology with engineering to find solutions to complex biological problems. MIMIC will be relevant

SBIO claims that SB939 is designed to be a best-in-class HDAC inhibitor, and has demonstrated the potential to bring additional therapeutic benefits due to its high potency, superior

The study also is also expected to investigate the pharmacokinetics of KAI-4169 and its effect on parathyroid hormone (PTH) and serum calcium levels. The data from Phase 1

The Perrigo product is a proton pump inhibitor and antacid indicated for the treatment of frequent heartburn. Perrigo has also provided prior notice of this filing to Schering-Plough